Degussa focusing strategy continues
German speciality chemical giant Degussa AG announced this week the
sale of its ASTA Medica Onkology business to Baxter Healthcare S.A.
sale of its ASTA Medica Onkology business to Baxter Healthcare S.A.
German speciality chemical giant Degussa AG announced this week the sale of its ASTA Medica Onkology business to Baxter Healthcare S.A., a Swiss subsidiary of US company Baxter International. The US healthcare products and services group paid Euro 525 million but details of the contract were not disclosed. The transaction, subject to approval by the antitrust authorities in Germany and the USA, is expected to be completed before the end of the year. The sale of ASTA Medica Onkology is part of Degussa's focusing strategy which has seen more than 70 per cent of its Euro 6.5 billion operations earmarked and sold within the past six months.
